Big pharma streamlines the process of drug development
The world's leading pharmaceutical giants, including GlaxoSmithKline (GSK), Merck & Co, Johnson & Johnson and Sanofi, are exploring the potential of artificial intelligence to help optimize the process of inventing new drugs.
On July 2, the British GlaxoSmithKline signed an agreement with the company Exscientia — the developer of AI systems — for $ 43 million, according to Reuters.
The goal of pharmaceutical companies is to use modern supercomputers and machine systems with artificial intelligence to calculate how molecules will behave in the new formula, and the probability with which they will make the new drug useful, thus saving time and money on unnecessary tests.
"Many large pharmaceutical companies are beginning to realize the potential of this approach and explore how it can help improve the efficiency of their business," said Andrew Hopkins, CEO of Exscientia, with which GSK has signed an agreement.
Hopkins, who previously worked at Pfizer, said that the AI system Exscientia could supply drugs, about 75% faster and cheaper compared to traditional approaches.
More news:
Show more
Чего мы добились
Available 8:00 - 18:00
Copyright © 2015 · GMP-audit
+7 499 110-25-29
Operating time: 8:00 - 18:00
LLC " Eurasia farm Consulting"
Legal address: Moscow, Orlikov lane, 5 page 2.
Actual address: Moscow, Luzhnetskaya embankment, 6, p. 1, of.206A
Write to us!
Content Oriented Web
Make great presentations, longreads, and landing pages, as well as photo stories, blogs, lookbooks, and all other kinds of content oriented projects.